Surf Wiki
Save to docs
general/angiotensin-ii-receptor-antagonists

From Surf Wiki (app.surf) — the open knowledge base

Eprosartan

Angiotensin II receptor antagonist

Angiotensin II receptor antagonist

| Drugs.com =

| elimination_half-life = 5 to 9 hours

Eprosartan, sold under the brand name Teveten among others, is an angiotensin II receptor antagonist used for the treatment of high blood pressure.

Eprosartan is sometimes paired with hydrochlorothiazide.

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.

History

The compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the Biovail Corporation.

References

References

  1. "Eprosartan mesylate- eprosartan mesylate tablet, film coated".
  2. (3 January 2012). "Teveten HCT- eprosartan mesylate and hydrochlorothiazide tablet".
  3. (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press..
  4. Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see [http://www.datamonitor.com/store/News/abbott_laboratories_kos_pharmaceuticals_a_wise_buy?productid=0BE8B1AB-14F9-4B92-99D2-80E8DC7ECA16], accessed 29 January 2015.
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

angiotensin-ii-receptor-antagonists imidazoles thiophenes drugs-developed-by-abbvie benzoic-acids
Want to explore this topic further?

Ask Mako anything about Eprosartan — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report